Vietnam's Biobanking Market Could Exceed US$700 Million by 2030

Vietnam's growing investment in biotechnology, genomics, precision medicine and pharmaceutical research is increasing the importance of biobanking as the country develops the infrastructure required for advanced biomedical research.

According to Insights10, the Vietnam Biobanks Market was valued at US$383.70 million in 2023 and is projected to reach US$702.77 million by 2030, representing a compound annual growth rate of 9.03%. The research identifies precision medicine, genetic testing, increasing disease burden and national genome initiatives among the principal drivers of market development.

Biobanks are organised repositories that collect, process, store and manage biological samples together with associated clinical and research data. These samples can include blood, plasma, serum, tissue, DNA, RNA, cells and other biological materials.

Their importance is growing as healthcare and life sciences become increasingly data-driven.

Biobanking supports areas including genomics, precision medicine, cancer research, drug discovery, clinical trials, biomarker discovery, regenerative medicine and population-health research.

Genomics creates a major opportunity

One of the strongest drivers for biobanking is the rapid expansion of genomic research.

Large-scale genomic studies require access to high-quality biological samples linked to accurate clinical and demographic information. Biobanks provide the infrastructure needed to collect and preserve these samples consistently over long periods.

This is particularly important for Vietnam because populations across Southeast Asia remain comparatively underrepresented in many international genomic databases.

Developing larger Vietnamese biospecimen collections could therefore help researchers better understand the genetic characteristics of the population and potentially support development of more relevant diagnostics and therapies.

Vietnam is building its biobanking infrastructure

Evidence of this development comes from a recent peer-reviewed study specifically examining Vietnam.

The 2026 Vietnam Biobanking Feasibility Study reports that Vietnam's biotechnology capabilities have advanced considerably, with the country's focus expanding from agricultural biotechnology into medical biotechnology, vaccine development and pharmaceuticals. Government strategies have supported research capabilities and infrastructure, including biobanks.

The study also highlights continuing challenges around infrastructure, sample management, expertise and capacity—suggesting considerable scope for future investment and international collaboration.

Precision medicine increases the value of biospecimens

Biobanking is becoming particularly important as healthcare moves towards precision medicine.

Rather than treating every patient with the same disease identically, precision medicine uses information about genetics, biomarkers, environment and lifestyle to understand why patients may develop different forms of disease or respond differently to treatment.

This requires access to large collections of well-characterised biological samples.

Cancer represents an important example. Tumour tissue, blood and circulating DNA can be stored and subsequently analysed using technologies including next-generation sequencing, proteomics, immunohistochemistry and liquid biopsy.

As Vietnam expands these capabilities, biobanks can provide the biological foundation connecting individual diagnostic technologies into a broader precision-medicine ecosystem.

Clinical trials and drug discovery create further demand

Vietnam's developing clinical-research sector represents another opportunity.

Biobanks can store samples collected during clinical trials, enabling pharmaceutical companies and researchers to perform biomarker studies, pharmacogenomic analysis and retrospective research.

They are also valuable in drug discovery, where researchers require access to biological material representing different diseases and patient populations.

This connects biobanking directly with Vietnam's wider ambitions in pharmaceutical R&D, biotechnology and clinical research.

Automation transforms sample management

Modern biobanks are becoming increasingly automated.

Large facilities can contain hundreds of thousands or even millions of biological samples, making manual storage and retrieval increasingly impractical.

The commercial ecosystem therefore extends beyond freezers and cryogenic storage to include automated sample handling, laboratory robotics, barcode and RFID tracking, Laboratory Information Management Systems (LIMS), temperature monitoring, backup power and specialist biobank-management software.

6Wresearch's dedicated Vietnam study segments the market across equipment, consumables, services and software, with applications including regenerative medicine, life-science research and clinical research.

AI could unlock the value of biobank data

Artificial intelligence could make biobanks even more valuable.

The samples themselves represent only part of the opportunity. When genomic, clinical, imaging and laboratory data associated with those samples are combined, researchers can potentially analyse enormous datasets to identify previously unknown disease patterns.

AI and machine learning can help researchers investigate relationships between genetics, biomarkers, disease progression and treatment response.

This moves biobanking beyond simply storing samples towards creating integrated biological and data resources for future healthcare research.

Asia-Pacific biobanking continues to expand

The regional market reinforces the growth opportunity.

MarketsandMarkets estimates the Asia-Pacific Biobanking Market at US$1.63 billion in 2025, forecasting it to reach US$2.57 billion by 2030, representing a 9.6% CAGR. Increasing precision-medicine adoption, genomic research, clinical trials and investment in healthcare infrastructure are identified as key growth drivers.

Other research providers use substantially broader definitions. Grand View Research, for example, estimates the Asia-Pacific biobank market at US$18.49 billion in 2025, reaching US$38.39 billion by 2033, at a 9.7% CAGR.

The huge difference between these figures demonstrates why market definition matters particularly strongly in biobanking.

A growing opportunity across Vietnam's life-sciences ecosystem

For Vietnam, the opportunity extends well beyond organisations operating biobanks themselves.

Growth creates demand for ultra-low-temperature freezers, cryogenic storage, laboratory automation, sample-management systems, LIMS, reagents and consumables, genomic sequencing, laboratory equipment, data platforms, cybersecurity and specialist biobanking services.

The market also connects multiple areas of Vietnam's developing life-sciences sector: genomics, proteomics, clinical trials, molecular diagnostics, cancer research, pharmaceutical R&D and precision medicine.

As Vietnam strengthens its biotechnology and medical-research capabilities, access to high-quality, well-characterised biological samples will become increasingly important.

With Vietnam-specific research forecasting the biobanks market to reach US$702.77 million by 2030, biobanking represents an important enabling sector within the country's emerging life-sciences economy.

READ THE FULL INSIGHTS REPORT